Cancer Patients Cumulatively Saved Around Rs 294 Crore Due To Price Control: JP Nadda

New Delhi: The government makes all efforts to ensure affordable and accessible treatment is available for cancer patients amid a rise in cases in India, Health Minister JP Nadda said on Friday.

Replying to supplementary questions during Question Hour in the Lok Sabha, Nadda said the government made all efforts to ensure that affordable and accessible treatment was available to the patients.

“The number of cancer cases is going up, it is increasing by almost 2.5 per cent every year,” Nadda said.

In men, cases of oral and lung cancer are on the up while more women are getting breast cancer, he added.

More than 1.55 million cancer cases are being registered every year, Nadda said.

“There is a list of 131 essential cancer medicines, which are in Schedule 1, (that) are monitored and (their) pricing is decided by the government. These are the commonly used medicines,” Nadda said.

He said patients cumulatively saved around Rs 294 crore due to this price control.

“There are 28 combinations, which are not in this list but the NPPA (National Pharmaceutical Pricing Authority) and the government have controlled their pricing as well,” he said.

“We have tried to make cancer drugs affordable,” he added.

Responding to another question on healthcare infrastructure, Nadda said the government was apprised of the matter and expansion of medical colleges were happening so that there could be more doctors.

“There should be a balance in quality and quantity of medical education. We are trying to go as fast as we can but, at the same time, (we) do not want to compromise on the quality of medical doctors,” he said.

Nadda informed the House that the number of medical colleges had gone up from 387 in 2014 to 731 at present while the number of MBBS seats rose from 51,348 seats to 1,12,112 (1.12 lakh) during the same period.

The number of postgraduate seats for medical students has gone up from 31,185 in 2014 to 72,627 at present, he added.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit